China's leading pharmaceutical firm Yabao Pharmaceutical has inked a pact with the University of South Australia, to develop new treatments for cancer.Under the terms of the deal, the University will identify drug candidates in a co-funded laboratory led by the University's professor Shudong Wang.
After speaking with more than 20 senior biotechnicians in Taiwan’s biotechnology industry, The Biotechnician has come up with a list of five major trends that are shaping, molding an impacting Taiwan’s biotechnology industry.
1.Strong Government Support for Biotechnology- The Taiwan government has implemented policies and rules to ensure that its biotechnology, pharmaceutical and medical device sectors are able to compete globally. In other words, the government has made these three industries key priorities.
Beijing government recently announced China's Sinovac Biotech as the supplier of the seasonal influenza vaccine for its 2015 vaccination campaign. The Beijing government said that it planned to order a minimum of 1.2 million doses of the seasonal flu vaccine from four manufacturers for its 2015 campaign.
A research team has developed a tumor-detecting chip using plasmonic gold nanoparticles and microwave technology, with their findings having the potential to be extended to preventive medicine and personalized medicine.
The team, led by National Chung Hsing University chemistry professor Lin Kuan-jiuh (林寬鋸), discovered that gold nanoparticles, when differently sized, exhibit different colors, which can be used to detect different target molecules, Lin told a news conference in Taipei on Wednesday.
Researchers in Korea have determined the possibility that adult mesenchymal stem cells (MSCs) may extend healthy life and lifespan by intravenous injections.
Professor Kim from Chungbuk National University and Dr. Ra from Biostar, as a joint research team, announced that the discovery was published in International Journal of Medicine, 'Stem Cells Translation Medicine' (IF 5.7) on August 27, 2015.
The study, which is selected as the featured paper, intends to introduce the research to the public. As a result of monthly intravenous injections of 1 million human adipose-derived stem cells into 10-month old rats until their death, cognitive function such as learning and memory improved and lifespan was extended by 31.3% through regeneration of blood vessels in the brain and muscles.
Nearly 40 percent of current drug targets – for diseases including diabetes, cancer and mental disorders – come from a family of proteins, called GPCRs, about which little is known. But an international group of pharma partners have formed an open-source, pre-competitive collaboration, called the GPCR Consortium, to solve the protein structures and understand modes of action.
The four newest members, announced today, include: Pfizer, Inc. (United States), H. Lundbeck A/S (Denmark), Boehringer Ingelheim (Germany), and Taisho Pharmaceutical (Japan).
Sandoz, a Novartis company, has received USFDA approval to launch first biosimilar drug, Zarxio (filgrastim-sndz), in United States.
"As the pioneer and global leader in biosimilars, Sandoz has maintained a commitment to bringing high-quality biosimilar medicines to patients and healthcare professionals around the world," said Mr Richard Francis, global head, Sandoz. "With the launch of Zarxio, we look forward to increasing patient, prescriber and payor access to filgrastim in the US by offering a high-quality, more affordable version of this important oncology medicine."
The Biotechnician produces daily news and intelligence on the most creative biotechnology and drug developments across the Asia Pacific. With experts and editors across Asia, The Biotechnician comments on breaking news while it occurs, and provides an insightful perspective to Asian based biotechnology firms, the development of medicines in the region, transactions that are occurring in the market, and regulatory issues that are preventing the development of the industry across the region.